Assuming that the probability of AIBL in patients with hormone receptor-positive breast cancer treated with aromatase inhibitors is P, Logit(P) = −1.272 + 0.079 * (duration of breast cancer) + 3.673 * (hip fracture index) − 0.007 * (PRL). This evidence concerns the gene NR4A1 and breast cancer.